MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.82
-1.02
-11.54%
Closed 16:41 04/01 EDT
OPEN
8.46
PREV CLOSE
8.84
HIGH
8.78
LOW
7.44
VOLUME
229.60K
TURNOVER
--
52 WEEK HIGH
13.95
52 WEEK LOW
5.36
MARKET CAP
231.76M
P/E (TTM)
-2.3740
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CNCE stock price target is 21.63 with a high estimate of 30.00 and a low estimate of 11.00.

EPS

CNCE News

More
  • Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata
  • Business Wire · 22h ago
  • Concert Pharma outlines late-stage CTP-543 trials in Alopecia Areata
  • Seeking Alpha - Article · 23h ago
  • Some Concert Pharmaceuticals (NASDAQ:CNCE) Shareholders Are Down 47%
  • Simply Wall St. · 6d ago
  • Edited Transcript of CNCE earnings conference call or presentation 27-Feb-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/12 00:23

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About CNCE

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
More

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.